CSIMarket Company Name, Ticker, Customers, else..
 
Bionano Genomics Inc   (NASDAQ: BNGO)
 
Price: $1.2200 $0.05 4.274%
Day's High: $1.2200000286102295 Week Perf: -2.4 %
Day's Low: $ 1.15 30 Day Perf: 14.02 %
Volume (M): 176,815 52 Wk High: $ 5.50
Volume (M$): $ 0 52 Wk Avg: $1.48
Open: $1.18 52 Wk Low: $1.00



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 12
 Employees 97
 Revenues (TTM) (Millions $) 30
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Bionano Genomics Inc is a biotechnology company based in San Diego, California. The company specializes in developing and commercializing cutting-edge genome analysis systems and tools. Bionano Genomics' flagship product is the Saphyr system, which is used for high-resolution structural variation detection and genome mapping. This system provides researchers and clinicians with a comprehensive view of genomes at unrivaled scale and resolution. Bionano Genomics' technology has applications in various fields such as clinical research, cancer genomics, and prenatal genetic testing. The company aims to revolutionize genomics research and advance precision medicine through its innovative solutions.


   Company Address: 9540 Towne Centre Drive San Diego 92121 CA
   Company Phone Number: 888-7600   Stock Exchange / Ticker: NASDAQ BNGO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ILMN   -4.3%    
TXG   -2.12%    
NTRA   -1.76%    
• View Complete Report
   



Product Service News

CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Geneti...

Published Mon, Sep 15 2025 11:16 AM UTC

Pioneering a New Era: Bionano Genomics OGM Receives Preliminary CMS Payment DeterminationIn a significant development for genomic medicine, Bionano Laboratories, a subsidiary of Bionano Genomics, Inc. (NASDAQ: BNGO), announced on September 15, 2025, that the Centers for Medicare & Medicaid Services (CMS) has published a preliminary payment determination for a new Category ...
Management Announcement

Amidst Financial Hurdles, Bionano Genomics Pioneers Optical Genome Mapping as an Innovative Solution for Genetic Diagnostics,

Published Wed, Apr 23 2025 12:01 PM UTC

IntroductionBionano Genomics, Inc. (Nasdaq: BNGO) has made significant strides in the field of genetic diagnostics with its innovative Optical Genome Mapping (OGM) technology. Recent peer-reviewed publications highlight OGM s accuracy and cost-effectiveness in identifying and sizing large repeat expansions associated with numerous genetic disorders. However, alongside these ...
Stock Market Announcement

Bionano Genomics Thrives: Strategic Proxy Support and Breakthroughs in Cytogenetics Pinpoint Future Growth Amidst Rising Share Prices,

Published Thu, Dec 19 2024 1:00 PM UTC

Bionano Genomics: Navigating Proxy Proposals and Promising Advancements in CytogeneticsIn recent months, Bionano Genomics Inc. has captured the attention of investors and stakeholders within the biotechnology sector as it advances its strategic objectives. The company announced the publication of a stockholder letter supporting a proxy proposal, coupled with pivotal researc...
Clinical Study

Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogeneti...

Published Mon, Dec 23 2024 1:30 PM UTC

Optical Genome Mapping Outperforms Traditional Cytogenetic Assays in Bone and Soft Tissue Tumor Analysis: A Study by Johns Hopkins University Recent advancements in genetic analysis techniques have brought transformative potential to the field of oncology. The emergence of Optical Genome Mapping (OGM) represents a breakthrough capable of surpassing conventional cytogenetic ...
Stock Market Announcement

Bionano Genomics Faces Stockholder Dissent as Strategic Growth and Funding Clash,

Published Thu, Oct 31 2024 12:10 PM UTC

Navigating Uncertainty: Bionano Genomics Strategic Growth Amidst Stockholder DiscontentIn a notable development in the biotechnology sector, Bionano Genomics recently announced the adjournment of its Special Meeting of Stockholders due to a lack of quorum. This postponement, which occurred on October 3, 2024, reflects the ongoing challenges the company faces as it strives t...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.47
Price to Sales (Expected) -
Price to Book 0.45
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.04
Working Capital Ratio 2.66
Leverage Ratio (MRQ) 0.51
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.45 $
Revenues (TTM) 2.61 $
Cash Flow (TTM) 0.12 $
Cash 0.9 $
Book Value 2.74 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 311,093
Net Income per Employee (TTM) -331,567
Receivable Turnover Ratio (TTM) 6.62
Inventory Turnover Ratio (TTM) 9.03
Asset Turnover Ratio (TTM) 0.42

Profitability Ratios Current
Gross Margin (MRQ) 52.8 %
Operating Margin (MRQ) -88.34 %
Net Margin (MRQ) -90.85 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Bionano Genomics Inc's Segments
Product    168.73 % of total Revenue
Services and other    11.6 % of total Revenue
Instrument Revenue    36.7 % of total Revenue
Consumable Revenue    100.17 % of total Revenue
Software Revenue    31.86 % of total Revenue
Product revenue    67.52 % of total Revenue
EMEA    102.72 % of total Revenue
Reportable Segment    181.84 % of total Revenue

  Bionano Genomics Inc Outlook

On March 5 2024 the Bionano Genomics Inc provided following guidance

Bionano Genomics, Inc. announced its financial results for the fourth quarter and full year of 2023, showing positive growth and momentum in its business operations. The company reported a strong performance in revenue generation during this period, highlighting the success of its innovative genomics solutions in the market.

Looking ahead to 2024, Bionano Genomics forecasts continued growth and expansion in its revenue streams. The company anticipates increased demand for its cutting-edge genomics technology and services, which are revolutionizing the field of genetic research and diagnostics. With a strong pipeline of products and services, Bionano Genomics is well-positioned to capitalize on the gro...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.